TDC
PRME icon

Thompson Davis & Co’s Prime Medicine PRME Stock Holding History

Thompson Davis & Co’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$53.8K Sell
14,590
-2,650
-15% -$8.8K 0.03% 159
2026
Q1 		$60K Sell
17,240
-5,500
-24% -$20.9K 0.04% 132
2025
Q4 		$78.9K Sell
22,740
-4,833
-18% -$21.5K 0.05% 139
2025
Q3 		$153K Buy
+27,573
New +$112K 0.09% 125

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
ACM
Alessandra Capital Management Torrance, California $141M AUM
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
KFGK
Keystone Financial Group (Kentucky) Lexington, Kentucky $1.69B AUM 40.17% 1-Year Est. Return
CIA
Concurrent Investment Advisors Tampa, Florida $11.8B AUM 31.86% 1-Year Est. Return

Thompson Davis & Co's PRME Position: Q2 2026 in Review

Thompson Davis & Co reduced its Prime Medicine (PRME) stake by 15% in Q2 2026, selling an estimated $8.8K and leaving 14,590 shares worth $53.8K. The position accounts for 0.03% of the portfolio, ranked #159.

Thompson Davis & Co first reported a position in PRME in Q3 2025 and has held it in 4 quarters since. The position peaked at $153K in Q3 2025. 56 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Thompson Davis & Co held 14,590 shares of Prime Medicine worth $53.8K as of Q2 2026.
  • Thompson Davis & Co sold 2,650 Prime Medicine shares in Q2 2026, an estimated $8.8K.
  • Prime Medicine made up 0.03% of Thompson Davis & Co's portfolio in Q2 2026, its #159 holding.
  • Thompson Davis & Co first reported a position in Prime Medicine in Q3 2025 and has held it in 4 quarters since.
  • Thompson Davis & Co's Prime Medicine position peaked at $153K in Q3 2025.
  • 56 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Thompson Davis & Co's 13F filing for Q2 2026, filed 29 Jul 2026.